Abstract Cyclin-dependent kinase 4 (CDK4) and CDK6 are critical mediators of cellular
transition into S phase and are important for the initiation, growth and survival of many …

Normal cells explore multiple states to survive stresses encountered during development
and self-renewal as well as environmental stresses such as starvation, DNA damage, toxins …

Triple-negative breast cancer (TNBC) is highly aggressive with a poor clinical prognosis and
no targeted therapy. The c-Myc protein is a master transcription factor and a potential …

Mutational loss of CDKN2A (encoding p16INK4A) tumor-suppressor function is a key
genetic step that complements activation of KRAS in promoting the development and …

ABSTRACT C-Myc overexpression is a common finding in pancreatic cancer and predicts
the aggressive behavior of cancer cells. It binds to the promoter of different genes, thereby …

The MYC transcription factor, encoded by the c‐MYC proto‐oncogene, is activated by
growth‐promoting signals, and is a key regulator of biosynthetic and metabolic pathways …

Simple Summary Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors are widely used to
treat metastatic hormone receptor-positive/human epidermal growth factor receptor 2 …

Inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6i) delay progression of metastatic
breast cancer. However, complete responses are uncommon and tumors eventually relapse …

Despite huge efforts made in academic and pharmaceutical worldwide research, current
anticancer therapies achieve effective treatment in a limited number of neoplasia cases only …

Cancer is a complex disease of multiple alterations occuring at the epigenomic, genomic,
transcriptomic, proteomic and/or metabolic levels. The contribution of genetic mutations in …